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Aims The globalization of clinical trials has highlighted geographic variations in patient characteristics, event rates, and
treatment effects. We investigated these further in PARADIGM-HF, the largest and most globally representative
trial in heart failure (HF) to date.
...................................................................................................................................................................................................
Methods
and results
We looked at five regions: North America (NA) 602 (8%), Western Europe (WE) 1680 (20%), Central/Eastern Europe/
Russia (CEER) 2762 (33%), Latin America (LA) 1433 (17%), and Asia-Pacific (AP) 1487 (18%). Notable differences
included: WE patients (mean age 68 years) and NA (65 years) were older than AP (58 years) and LA (63 years) and had
more coronary disease; NA and CEER patients had the worst signs, symptoms, and functional status. North American
patients were the most likely to have a defibrillating-device (54 vs. 2% AP) and least likely prescribed a mineralocorticoid
receptor antagonist (36 vs. 65% LA). Other evidence-based therapies were used most frequently in NA and WE. Rates
of the primary composite outcome of cardiovascular (CV) death or HF hospitalization (per 100 patient-years) varied
among regions: NA 13.6 (95% CI 11.7–15.7) WE 9.6 (8.6–10.6), CEER 12.3 (11.4–13.2), LA 11.2 (10.0–12.5), and AP
12.5 (11.3–13.8). After adjustment for prognostic variables, relative to NA, the risk of CV death was higher in LA and AP
and the risk of HF hospitalization lower in WE. The benefit of sacubitril/valsartan was consistent across regions.
...................................................................................................................................................................................................
Conclusion There were many regional differences in PARADIGM-HF, including in age, symptoms, comorbidity, background
therapy, and event-rates, although these did not modify the benefit of sacubitril/valsartan.
...................................................................................................................................................................................................
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Introduction
The declining risk of adverse outcomes in patients with heart failure
(HF) and reduced ejection fraction (HF-REF), resulting from the
cumulative benefit of treatments over time, has meant that contem-
porary randomized controlled clinical trials require greater numbers
of participants and longer follow-up to accrue the number of events
needed to test the effect of new therapies.1 In order to recruit a suffi-
cient number of patients in a timely manner, and to improve general-
izability of results, these trials now include participants from many
different regions of the world.2 On the other hand, geographical dif-
ferences in demographics, race, ethnicity, other patient characteris-
tics, aetiology of HF, co-morbidity, health care systems, physician-
practice, and especially background therapy can raise questions about
the applicability of the results of the trial in certain regions of the
world.2–14 In particular, there has been controversy about the effect
of certain treatments in patients from the USA compared with those
from the rest of the world.3,15–17
The prospective comparison of Angiotensin Receptor-neprilysin
inhibitor with Angiotensin-converting–enzyme inhibitor to Deter-
mine Impact on Global Mortality and morbidity in Heart Failure
trial (PARADIGM-HF) is the largest trial in patients with HF and
HF-REF to date and it is the most globally representative,
with 8400 patients enrolled in 47 countries on six continents.18
Our aim was to evaluate geographical differences in patient
characteristics (age, sex, background pharmacotherapy, and comor-
bidity) and event rates. We also wanted to examine the effect of
sacubitril/valsartan (formerly known as LCZ696) according to geo-
graphical region. Our hypothesis was that patient characteristics and
outcomes would vary by geographic region in PARADIGM-HF but
that the effect of sacubitril/valsartan, compared with enalapril, would
not.
Methods
The design, baseline characteristics, and results of PARADIGM-HF have
been published.18–20 The Ethics Committee of each of the 1043 partici-
pating institutions (in 47 countries) approved the protocol, and all
patients gave written, informed consent.
Study patients
Briefly, patients had New York Heart Association (NYHA) classes II–IV
symptoms, a left ventricular ejection fraction (LVEF)40% and modestly
elevated plasma B-type natriuretic peptides. Patients were required to be
taking an angiotensin converting enzyme inhibitor or angiotensin recep-
tor blocker in a dose equivalent to enalapril 10 mg daily for at least 4
weeks before screening, along with a stable dose of a b-blocker
(unless contraindicated or not tolerated) and a mineralocorticoid antago-
nist (MRA), if indicated. Key exclusion criteria included a systolic blood
pressure (SBP) <95 mmHg, a serum potassium >5.4 mmol/L, or an esti-
mated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 at
randomization.
Trial outcomes
The primary outcome was a composite of death from CV causes or a first
hospitalization for HF. The secondary outcomes included death from any
cause and change from baseline to 8 months in the Kansas City
Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS). In
the present study, we examined the primary composite outcome and its
components, as well as all-cause death. We further determined the propor-
tion of patients experiencing a five or greater points reduction in their
KCCQ-CSS as this is considered to be a clinically important deterioration
in health-related quality of life (HRQL).21 Safety outcomes included hypo-
tension, elevation of serum creatinine, hyperkalaemia, cough, and angioe-
dema, as previously reported.18 We also reported total number of adverse,
and serious adverse events according to geographic region. Furthermore,
we assessed length of stay for all-cause hospitalizations during the study,
and total days alive and out of hospital in the first year (Figure 1).
Geographic regions
The following geographic regions were examined: North America (NA),
Western Europe (WE), Central/Eastern Europe/Russia (CEER), Latin
America (LA), and the Asia-Pacific (AP) region. The countries in each of
these regions are listed in Appendix.
Statistical analysis
Data are reported as mean6 SD or median and interquartile ranges and
as frequencies and percentages for categorical variables. Student’s t-tests
were used to compare baseline variables between regions. Cox propor-
tional hazard models were used to estimate hazard ratios (HRs) with 95%
confidence intervals (CIs) for the time-to-event endpoints, and logistic
regression analysis for the binomial endpoint of 5 point decline in
KCCQ-CSS at 8 months follow-up. In analyses of treatment effect, the pri-
mary variable of interest was the interaction P-value for randomized treat-
ment  geographic region. For analyses comparing risk according to
region, we did unadjusted analyses and analyses including multivariable
adjustment for treatment effect and other variables known to be predictors
of risk in patients with HF-REF (see Supplementary material online, List). A
two-tailed P-value of <0.05 was considered significant. Statistical analyses
were performed using STATA, College Station, Texas, version 14.0.
Results
Of 8399 patients in PARADIGM-HF, 602 (7%) were randomized in
NA, 1680 (20%) in WE, 2762 (33%) in CEER, 1433 (17%) in LA, and
1487 (18%) in the AP region.
Baseline characteristics
The majority of characteristics differed across regions (Table 1 and
see Supplementary material online, Tables A and B).
Age, sex, and race/ethnicity
Patients in WE, who were the most elderly (with a mean age 68.3
years), were an average of 10.5 years older than those enrolled in AP.
The proportion of women was highest in LA (27%) and lowest in NA
3168 S.L. Kristensen et al.
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(17%). The proportion of patients who were black was highest in NA
(19%).
Social physiological measures
Body mass index varied by region, being highest in NA (31 Kg/m2)
and lowest in AP (24 kg/m2) (Table 1). Heart rate in patients without
atrial fibrillation (AF) was lowest in NA (70 b.p.m.) and WE (68
b.p.m.) and highest in AP (75 b.p.m.), consistent with the geographical
variation in b-blocker use but inversely related to digoxin use (see
below). Baseline SBP was highest in CEER (mean 126 mmHg) com-
pared with 117 mmHg in AP and 118 mmHg in NA and LA, consis-
tent with geographical variation in hypertension history (see below).
Coronary heart disease
An ischaemic aetiology was most common in CEER (70%) and NA
(63%) and least common in LA (43%). Consistent with this, history of
myocardial infarction was most frequent in CEER (50%) and NA
(55%) and least frequent in LA (32%) and AP (34%). The proportions
of patients with any manifestation of coronary disease and prior cor-
onary revascularization varied in a similar way (Table 1).
Other co-morbidity
Co-morbidity was generally most common in NA (except a history
of hypertension and AF which was highest in CEER). Co-morbidity
was less common in LA and AP. The proportion of patients with
chronic kidney disease (CKD) was lowest in AP (27%) and mean
eGFR highest in that region (72 mL/min/1.73 m2); mean eGFR was
lowest in NA (59 mL/min/1.73 m2), where there was also the great-
est proportion with CKD (52%).
Drug, device, and other treatments
Although b-blocker use was mandated by protocol (unless contrain-
dicated/not tolerated), there was still variability with the highest rate
in NA (97%) and lowest in AP (89%) (Table 2). There was more strik-
ing variation in the use of mineralocorticoid receptor antagonists—
prescribed least commonly in NA (36%) and most frequently in LA
(65%). Digoxin use also varied greatly in patients with no history of
AF—from 6% in WE to 42% in AP. There was less variation in digoxin
use among patients with a history of AF (range 33% WE to 55% AP).
The use of non-HF medications also varied geographically. The
highest rates of prescription of oral anticoagulants in patients with an
AF history were in Europe (WE 82%, CEER 68%) and NA (63%) and
lowest in AP (35%).
Device therapy varied substantially by region, being highest in NA
and lowest in CEER, LA, and AP. For example, a defibrillating-device
(ICD or CRT-D) had been implanted in 54% in NA but in only 7, 4,
and 2% of patients in CEER, LA, and AP, respectively. Similarly, other
Figure 1 Kaplan–Meier plots of endpoints according to region.
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.guideline-recommended interventions varied by region. Influenza
vaccination in the past year was most frequently reported in NA
(53%) and WE (53%) but much less commonly elsewhere. A quarter
to a third of patients in NA and WE were enrolled in a structured dis-
ease management programme but few patients were enrolled else-
where. Prescription of an exercise regimen was provided in between
a fifth and a quarter of patients in NA, WE, and CEER but was
uncommon elsewhere. These non-drug/device interventions were
rarely used in AP.
Heart failure outcomes
Cardiovascular death or heart failure hospitalization
The unadjusted rate of the primary endpoint varied less between
regions than the rate of HF hospitalization, with the following ranking
from lowest to highest: WE (9.6 per 100 patient-years), LA, CEER,
AP, and NA (13.6 per 100 patient-years). Using NA as the reference
region, and after adjustment, WE exhibited a lower risk (adjusted HR
0.85. 95% CI 0.70, 1.02) but AP a higher risk (adjusted HR 0.85. 95%
CI 0.70, 1.02). A supplementary analysis including South Africa, Israel,
and Turkey in alternative geographical regions gave similar results
(see Supplementary material online, Table D). We also compared
Eastern/Central Europe and Russia (see Supplementary material
online, Table E); the crude rates of the primary endpoint were similar
but mortality rates were slightly higher and hospitalization rates
lower, in Russia.
Mortality
The unadjusted rate of death from any cause varied modestly among
regions with the following ranking from lowest to highest: WE (6.7
per 100 patient-years), NA, CEER, AP, and LA (10.1 per 100 patient-
years) (Table 3). Using NA as the reference and adjusting for differen-
ces between regions in prognostic variables, patients in LA (adjusted
HR 1.67, 95% CI 1.28, 2.19) and AP (HR 1.40, 95% CI 1.03, 1.91)
exhibited a higher risk of death. The findings for CV death were
similar.
Hospitalization
The unadjusted rate of HF hospitalization varied more among regions
with the following ranking from lowest to highest: LA (5.3 per 100
patient-years), AP, WE, CEER, and NA (10.7 per 100 patient-years).
Using NA as the reference, all other regions showed a significantly
lower unadjusted risk of hospitalization. After adjustment, this differ-
ence persisted only in WE (adjusted 0.79, 95% CI 0.63, 0.98). Length
of stay for hospitalization was shortest in NA and WE and longest in
CEER (see Supplementary material online, Table F). Days alive and
out of hospital in first year of study, varied between 345 and 351
days, with highest number in NA.
....................................................................................................................................................................................................................
....................................................................................................................................................................................................................
Table 1 Baseline characteristics according to region
North America Western Europe Central/Eastern
Europe/Russia
Latin America Asia-Pacific P-value
Number of patients 602 (7%) 1680 (20%) 2762 (33%) 1433 (17%) 1487 (18%)
Age (years) 65.16 11.4 68.36 9.9 65.16 10.0 63.06 11.6 57.86 11.9 <0.0001
Female sex, n (%) 104 (17%) 297 (18%) 641 (23%) 391 (27%) 292 (20%) <0.0001
Caucasian, n (%) 466 (77%) 1645 (98%) 2712 (98%) 485 (34%) 11 (1%) <0.0001
BMI (kg/m2) 316 7 296 5 306 5 276 5 246 4 <0.0001
Heart rate (b.p.m.) 706 11 696 11 746 12 716 11 756 11 <0.0001
Syst. BP (mmHg) 1186 15 1216 16 126 6 14 1186 14 1176 15 <0.0001
eGFR (mL/min/1.73 m2) 59 (48, 71) 61 (50, 74) 67 (55, 80) 67 (55, 80) 72 (59, 85) <0.0001
LVEF 0.276 0.07 0.306 0.06 0.326 0.05 0.286 0.06 0.286 0.06 <0.0001
NYHA class, n (%) <0.0001
I 23 (4%) 58 (4%) 33 (1%) 107 (7%) 119 (8%)
II 456 (76%) 1292 (77%) 1512 (55%) 1168 (82%) 1180 (79%)
III 117 (19%) 319 (19%) 1169 (42%) 156 (11%) 184 (13%)
IV 4 (1%) 7 (0%) 45 (2%) 0 (0%) 3 (0%)
KCCQ score 716 21 736 20 686 19 796 18 796 16 <0.0001
NT-proBNP pg/mLa (IQR) 1582 (897, 3080) 1517 (857, 2888) 1599 (877, 3134) 1760 (917, 3645) 1714 (911, 3677) 0.0003
Medical history, n (%)
Ischaemic aetiology 381 (63%) 980 (58%) 1942 (70%) 617 (43%) 863 (58%) <0.0001
HF hospitalization 394 (65%) 948 (56%) 1961 (71%) 773 (54%) 894 (60%) <0.0001
Hypertension 503 (84%) 1050 (63%) 2395 (87%) 975 (68%) 719 (48%) <0.0001
Atrial fibrillation 239 (40%) 744 (44%) 1428 (52%) 340 (24%) 249 (17%) <0.0001
Diabetes 293 (49%) 597 (36%) 936 (34%) 391 (27%) 515 (35%) <0.0001
CKD (eGFR < 60b) 311 (52%) 759 (45%) 950 (34%) 494 (35%) 397 (27%) <0.0001
aNT-proBNP data are from the screening visit. Information on KCCQ score was only available for 7623 (92%) patients.
bmL/min/1.73 m2.
3170 S.L. Kristensen et al.
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Health-related quality of life
The proportion of patients exhibiting a decrease of 5 points in
KCCQ-CSS at 8 months was largest in NA, WE, and CEER (where
around a third of patients deteriorated) and smaller in LA (24%) and
AP (18%). The odds of deteriorating were significantly less in these
latter regions in unadjusted analyses, but not after multivariable
adjustment.
Consistency of effect of sacubitril/
valsartan on clinical outcomes by region
As shown in Table 4, the effect of sacubitril/valsartan was consistent
across regions for the primary composite endpoint, its components
and for all-cause mortality. The same was true for the effect of sacubi-
tril/valsartan on deterioration in KCCQ.
Study drug tolerability
Adverse events varied considerably by region (see Supplementary
material online, Table C). In the enalapril group, hypotension and renal
impairment were most common in NA, hyperkalaemia was most
common in CEER and cough most common in AP. The differences
between sacubitril/valsartan and enalapril (more hypotension and
less renal impairment and hyperkalaemia with the former) were con-
sistent across regions. Study drug discontinuation for reasons other
than death varied significantly by geographical region, from 32% in
NA to 10% in AP.
Discussion
Although there are a few analyses of geographic variation among
patients with acute HF, there is only one report from a trial, the
Assessment of Treatment with Lisinopril and Survival study (ATLAS),
in ambulatory patients with chronic HF-REF, published in
1998.3,7,8,10,11 No acute or chronic HF trial has been as globally
diverse as PARADIGM-HF which included patients from geographical
areas under-represented in prior studies including LA and, especially,
AP. More data were collected on baseline characteristics and treat-
ment in PARADIGM-HF than in prior trials, including information on
non-pharmacolgical/non-device recommendations, e.g. enrolment in
disease management programmes.
Baseline characteristics
We found some inevitable differences between regions (e.g. in race
and ethnicity), some possibly related to genetic background (e.g. low
prevalence of AF in AP22). It is harder to explain other differences.
Compared with NA and WE, where clinical trials were initially con-
ducted, the average patient age was lower (especially in AP) and the
proportion of women larger (especially in LA). Ischaemic aetiology
was least frequent in LA, which was also reported in two acute HF
trials, presumably reflecting different causes of HF on that continent,
including Chagas cardiomyopathy.7,8
Regarding HF status, we found that the greatest differences were
between CEER and the rest of the World. Specifically, CEER patients
had worse symptoms and more severe functional limitation as eval-
uated by the investigators (NYHA class) and reported by patients
(KCCQ-CSS). Consistent with this, signs (dyspnoea, oedema, and
rales) and prior HF hospitalization were more common. However,
patients from CEER had the highest average LVEF and lowest NT-
proBNP and, overall, examination of regional patterns showed no
clear relationship between objective measurements of cardiac dys-
function and symptom frequency and physical limitation.
As observed previously, the rate of prior coronary intervention
was highest in NA,7,8,11 followed closely by WE; patients in CEER had
less prior coronary intervention but the rates in this region were still
considerably higher than in LA and AP. Despite similar recommenda-
tions regarding ICD and CRT use in all major guidelines, an even
....................................................................................................................................................................................................................
....................................................................................................................................................................................................................
Table 2 Pharmacological and device treatment
North
America
Western
Europe
Central/Eastern
Europe/Russia
Latin
America
Asia-Pacific P-value
Medication, n (%)
Loop-diuretic 488 (81%) 1362 (81%) 2292 (83%) 1116 (78%) 1091 (73%) <0.0001
b-Blocker 586 (97%) 1570 (94%) 2612 (95%) 1322 (92%) 1320 (89%) <0.0001
MRA 217 (36%) 742 (44%) 1695 (61%) 924 (65%) 830 (56%) <0.0001
Digoxin
All 163 (27%) 307 (18%) 805 (29%) 499 (35%) 660 (44%) <0.0001
History of AF 96 (40%) 248 (33%) 647 (45%) 174 (51%) 136 (55%) <0.0001
No history of AF 67 (19%) 58 (6%) 155 (12%) 325 (30%) 523 (42%) <0.0001
Oral anticoagulants
All 199 (33%) 792 (47%) 1181 (43%) 280 (20%) 143 (10%) <0.0001
History of AF 149 (62%) 606 (82%) 964 (68%) 185 (54%) 87 (35%) <0.0001
No history of AF 50 (14%) 186 (20%) 217 (16%) 95 (9%) 56 (5%) <0.0001
Devices
Any CRT 130 (22%) 207 (12%) 113 (4%) 29 (2%) 42 (3%) <0.0001
ICD or CRT-D 327 (54%) 559 (33%) 193 (7%) 61 (4%) 26 (2%) 0.0033
MRA, mineralocorticoid receptor antagonist; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter defibrillator; AF, atrial fibrillation.
Geographic variations in PARADIGM-HF 3171
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.more extreme pattern of disparity of use was seen, with a 30-fold dif-
ference in use of a defibrillating-device between NA and AP.7,8,11 Of
all regional variation, use of procedures, devices, and surgery showed
the greatest differences, probably, in part, reflecting economic
differences.
Variation in HF medication use was less pronounced but was still
substantial, at least for MRAs. Prescription of MRAs showed exactly
the opposite pattern to use of devices i.e. was least common in NA
and WE and most frequent in the other regions with lower device
use. Patients in NA and WE had the lowest eGFR (and highest pro-
portion of patients with CKD) which may have led to reluctance to
prescribe, although the entry eGFR in PARADIGM-HF would not
have precluded safe use of a MRA, and other explanations may
exist.23 Among patients without a history of AF, there was also an
almost seven-fold difference in digoxin prescription, with the highest
use in AP (42%) and lowest use in WE (6%), illustrating the dramatic
decline in digitalis glycoside use in certain regions of the world (in
ATLAS 80% of sinus rhythm patients in NA and 57% in continental
Europe were treated with digoxin).3
Of non-HF drugs, the greatest variation was in use of oral anticoa-
gulants which were much less frequently prescribed in AP, where
under-treatment of AF patients with these agents has been high-
lighted recently.24
The use of other guideline recommendations, including influenza
vaccination, exercise prescription, and enrolment in disease manage-
ment programmes, varied greatly between regions. For example,
influenza vaccination was used in around half of patients in NA and
WE but rarely outside these regions. Similar patterns were observed
for the other non-drug/non-device recommendations.
Collectively, our data show the use of guideline-recommended
therapies is highest in NA and WE, with less application in CEER and
LA and least use in AP. The one striking exception was use of MRAs,
as described above.
Clinical outcomes
Despite the considerable heterogeneity in baseline characteristics
and treatment, the crude rate of all-cause mortality varied modestly
and was only clearly higher in one region—LA—compared with the
others. However, after adjustment the risk of all-cause and cardiovas-
cular death was found to be higher in LA and in AP, compared with
NA. Both of the former regions also had the highest average NT-
proBNP levels and lower LVEF (mean 28%) compared with the
....................................................................................................................................................................................................................
....................................................................................................................................................................................................................
....................................................................................................................................................................................................................
....................................................................................................................................................................................................................
....................................................................................................................................................................................................................
....................................................................................................................................................................................................................
Table 3 Event rate (per 100 patient-years) and risk of study endpoints according to region (North America reference
region)
North
America
Western
Europe
Central/Eastern
Europe and Russia
Latin
America
Asia-Pacific
No. of patients 602 1680 2762 1433 1487
HF hospitalization or cardiovascular death 180 358 694 314 369
Event rates per 100 patient-years (95% CI) 13.6 (11.7–15.7) 9.6 (8.6–10.6) 12.3 (11.4–13.2) 11.2 (10.0–12.5) 12.5 (11.3–13.8)
Unadjusted HR 1.00 (ref.) 0.70 (0.59–0.84) 0.89 (0.76–1.05) 0.81 (0.67–0.97) 0.90 (0.76–1.08)
Adjusteda HR 1.00 (ref.) 0.85 (0.70–1.02) 1.09 (0.90–1.32) 1.17 (0.93–1.49) 1.39 (1.06–1.80)
HF hospitalization 142 244 402 148 192
Event rates per 100 patient-years (95% CI) 10.7 (9.1–12.6) 6.5 (5.7–7.4) 7.1 (6.5–7.8) 5.3 (4.5–6.2) 6.5 (5.6–7.5)
Unadjusted HR 1.00 (ref.) 0.61 (0.49–0.75) 0.65 (0.54–0.79) 0.47 (0.38–0.60) 0.59 (0.47–0.73)
Adjusteda HR 1.00 (ref.) 0.79 (0.63–0.98) 0.94 (0.75–1.17) 0.80 (0.59–1.08) 0.99 (0.71–1.39)
Cardiovascular death 86 192 419 240 252
Event rates per 100 patient-years (95% CI) 5.7 (4.6–7.1) 4.8 (4.1–5.5) 6.8 (6.2–7.5) 8.2 (7.2–9.3) 8.0 (7.1–9.1)
Unadjusted HR 1.00 (ref.) 0.84 (0.65–1.08) 1.20 (0.95–1.51) 1.44 (1.12–1.84) 1.40 (1.10–1.79)
Adjusteda HR 1.00 (ref.) 0.95 (0.73–1.23) 1.30 (0.99–1.68) 1.84 (1.34–2.51) 1.81 (1.28–2.55)
All-cause mortality (no. of events) 119 271 510 295 279
Event rates per 100 patient-years (95% CI) 7.9 (6.6–9.5) 6.7 (6.0–7.6) 8.3 (7.6–9.1) 10.1 (9.0–11.3) 8.9 (7.9–10.0)
Unadjusted HR 1.00 (ref.) 0.85 (0.69–1.06) 1.06 (0.87–1.29) 1.29 (1.04–1.60) 1.14 (0.91–1.40)
Adjusteda HR 1.00 (ref.) 0.94 (0.75–1.17) 1.14 (0.91–1.42) 1.67 (1.28–2.19) 1.40 (1.03–1.91)
Significant worsening in KCCQ clinical
score (5) at 8 monthsb
205 (34%) 564 (34%) 870 (32%) 341 (24%) 264 (18%)
Unadjusted OR 1.00 (ref.) 0.98 (0.80–1.19) 0.89 (0.74–1.07) 0.60 (0.49–0.74) 0.42 (0.34–0.52)
Adjusteda OR 1.00 (ref.) 1.06 (0.86–1.30) 0.95 (0.77–1.17) 0.83 (0.64–1.07) 0.94 (0.70–1.25)
Information on KCCQ score was only available for 7623 (92%) patients.
ICD, ischaemic aetiology and history of myocardial infarction, diabetes, AF, and stroke.
aModel adjusted for age, sex, treatment arm, race, HF duration, heart rate, SBP, body mass index, NYHA class, ejection fraction, KCCQ score, and glomerular filtration rate.
bScores on the Kansas City Cardiomyopathy Questionnaire (KCCQ) range from 0 to 100 (higher scores indicating fewer symptoms).
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others (except NA which had the lowest LVEF–mean 27%).
However, the higher risk of death persisted (or even increased) after
adjusting for these and additional differences in known prognostic
variables suggesting other biological factors, social, and environmen-
tal influences or aspects of health care provision in these regions con-
tribute to the observed differences in survival. There may also be
geographical differences in the treatment of comorbidities such as
coronary artery disease, CKD, and AF which might also affect
outcome.
Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome
Study With Tolvaptan (EVEREST), the only other large trial reporting
long-term outcomes according to region (in patients with acute HF),
observed similar crude mortality rates in NA, LA, and WE (no
patients from AP were included).7 The adjusted risk of death was
highest in LA. The Aliskiren Trial on Acute Heart Failure Outcomes
(ASTRONAUT), another acute HF trial, is the only study to have
reported outcomes in AP as well as the Americas and Europe.11 In
that study, all-cause mortality at 12 months was highest in AP (and
high in LA). Interestingly, however, these other two studies reported
quite different findings about EE with the lowest risk of death in that
region in EVEREST but the second highest (after AP) in
ASTRONAUT. There has been recent controversy about a low
event rate in CEER17 and it is interesting that both PARADIGM-HF
and ASTRONAUT did not observe low event rates in this region.
Notably, unlike EVEREST, both PARADIGM-HF and ASTRONAUT
required elevated natriuretic peptides for inclusion, perhaps helping
ensure correct diagnosis and selection of patients at risk of events.
Greater variation in HF hospitalization rates, compared with mor-
tality, might have been predicted, given the likely differences in deci-
sion making about admission, community programmes to prevent
hospitalization, thresholds for admission and even provision and avail-
ability of hospital beds between regions. However, again, only one
region was clearly different from the others and that was NA, which
had almost twice the crude rate of HF hospitalization compared with
LA, although the differences between regions were greatly attenu-
ated by adjustment, with only WE having a significantly lower risk.
There was also no convincing evidence of ‘competing risk’ influencing
our findings, i.e. regions with higher mortality did not consistently
have lower admission rates. In ASTRONAUT, NA patients also had a
much higher unadjusted HF hospitalization rate than elsewhere,
although in EVEREST the crude re-admission rates did not vary
greatly between regions.7,11
Health-related quality of life
We are not aware of prior reports of geographic variation in patient-
reported outcomes. A clinically important deterioration in KCCQ-
CSS after 8 months was significantly less likely in LA and AP (in unad-
justed analyses) than elsewhere and it is notable that these two
regions had the highest baseline KCCQ-CSS (i.e. the best HRQL).
This finding illustrates the clear discrepancy between patient-
reported outcomes and clinical events, given that these two regions
had the highest all-cause and cardiovascular mortality rates.
Treatment effect
Despite the differences highlighted, we did not identify any modifica-
tion of the effect of sacubitril/valsartan by geographical region—the
benefit over enalapril was consistent for all outcomes across all
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regions, contrasting with controversy about consistency of benefit of
b-blockers in HF-REF and spironolactone in HF with preserved ejec-
tion fraction (HF-PEF).15–17
Implications
Globalization of clinical trials is a reality that has highlighted regional
disparities of many types.2,9,13 Some are demographic and biologically
determined and unavoidable whereas others reflect variation in clini-
cal practice and economic influences. Despite this, we found that the
key outcomes constituting trial endpoints varied less than has been
suggested previously. This may reflect more standardized inclusion
and exclusion criteria in HF-REF trials compared with trials in HF-PEF
and acute HF, and, in PARADIGM-HF in particular, the use of a
natriuretic peptide inclusion criterion. The latter may be an even
more important consideration in trials in patients with (HF-PEF).12
Although we found no variation in treatment effect by region, inevita-
bly questions will also remain about the applicability of the findings of
trials enrolling a large proportion of patients from regions where cer-
tain evidence-based therapies are substantially underused (e.g. MRAs
in NA and ICDs in the rest of the world).
Limitations
Our study has a number of limitations. Although PARADIGM-HF is
the largest HF trial to date, it is a single study. The analyses conducted
were retrospective and PARADIGM-HF was not designed to evalu-
ate geographical differences in HF. Because our analyses involved
comparisons of many different variables across several regions, statis-
tically significant differences may have arisen through the play of
chance. Although we performed multivariable adjustments, we may
not have captured the effect of all predictors influencing the out-
comes studied. While we examined recognized geographical regions,
differences may also exist between countries within these regions
and these may be more marked in some regions than others, e.g. AP
compared with NA. The number of patients recruited in NA was lim-
ited (n ¼ 622), although analyses showed similar benefit for these
patients compared with other regions. The low number of black
patients (n ¼ 6) in WE probably reflects selection bias in trial enrol-
ment. As with any trial, the generalizability of the findings to ‘real-
world’ patients may be limited.
Conclusion
There were many regional differences in PARADIGM-HF, including
in age, symptoms, comorbidity, background therapy, and event-rates,
although these did not modify the benefit of sacubitril/valsartan.
Supplementary material
Supplementary material is available at European Heart Journal online.
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